Skip to main content
SpringerLink
Log in

Radiation Therapy in Mantle Cell Lymphoma

  • Living reference work entry
  • First Online:
Radiation Oncology

  • 431 Accesses

Abstract

Mantle cell lymphoma (MCL) is a definitive subtype of non-Hodgkin’s lymphoma (NHL), first coined in the early 1990s. It is unfrequent and accounts for 6–8% of all NHLs in Europe, with increasing incidence during the past decades, particularly with regard to advanced stage disease. MCL shows the poorest prognosis of all lymphomas. Involvement of extranodal sites is common, MCLs present the highest rates of secondary gastrointestinal and extranodal involvement of all lymphomas. Most patients show symptoms due to a rapidly growing lymphadenopathy. Lymphoma classification should be based on pathological investigation of affected lymph nodes and the quantification of Ki-67 expression, considered as the most established biological risk factor in MCL, should always be determined at diagnosis. No dependable markers are verified to predict an indolent future behavior of MCL. Gastrointestinal (GI) involvement in MCL patients can lead to intestinal obstruction, perforation, or bleeding and these symptoms could require immediate surgical intervention. Due to advanced spread of the disease, at initial presentation most patients require intensive systemic treatment. Most patients present after the age of 65 and are not physically fit enough to cope with aggressive chemotherapy; they are treated with moderate immunochemotherapy regimens. For young and fit patients, aggressive immunochemotherapy followed by autologous stem cell transplantation (autoSCT) and maintenance therapy might be considered. A small share of patients presents with limited stage disease at initial diagnosis; they can benefit from radiotherapy to manage local disease, followed or preceded by a shortened chemotherapy regimen. Some patients might benefit from a wait-and-see strategy, without the immediate application of systemic or local therapy. However, it remains difficult to identify those patients. Treatment of MCL in the majority of cases remains palliative with commonly aggressive course of disease, long-term survival is just seen in few cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abbott S, Nikolousis E, Badger I. Intestinal lymphoma – a review of the management of emergency presentations to the general surgeon. Int J Color Dis. 2015;30(2):151–7.

    Article  CAS  Google Scholar 

  • Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1023–30.

    Article  CAS  PubMed  Google Scholar 

  • Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16(7):637–40.

    Article  CAS  PubMed  Google Scholar 

  • Barzenje DA, Holte H, Fosså A, Ghanima W, Liestøl K, Delabie J, et al. Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2017;58(3):623–32.

    Article  PubMed  Google Scholar 

  • Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S, et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia. 2001;15(11):1785.

    Article  CAS  PubMed  Google Scholar 

  • Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(9):1403–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European mantle cell lymphoma network. Ann Oncol. 2013;24(8):2119–23.

    Article  CAS  PubMed  Google Scholar 

  • Dreyling M. Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches. Proc Am Soc Clin Oncol; 2014 [cited 2017 May 22]. Available from: http://meetinglibrary.asco.org/content/114000191-144.

  • Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncologia. 2013;24(4):857–77.

    CAS  Google Scholar 

  • Dreyling M, Ferrero S, Vogt N, Klapper W. New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature? [internet]. AACR; 2014a [cited 2017 May 22]. Available from: http://clincancerres.aacrjournals.org/content/20/20/5194.short.

  • Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014b;25(Suppl 3):83–9.

    Article  Google Scholar 

  • Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–8.

    Article  CAS  PubMed  Google Scholar 

  • Engelhard M, Unterhalt M, Hansmann M. Follicular lymphoma, immunocytoma, and mantle cell lymphoma: randomized evaluation of curative radiotherapy in limited stage nodal disease. Ann Oncol 2008;19 (suppl. 4):418.

    Google Scholar 

  • Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408–18.

    Article  PubMed  Google Scholar 

  • Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;108(13):4003–8.

    Article  CAS  PubMed  Google Scholar 

  • Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al. Cyclin D1–negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106(13):4315–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015;168(1):55–62.

    Article  CAS  PubMed  Google Scholar 

  • Guru Murthy GS, Venkitachalam R, Mehta P. Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the surveillance, epidemiology and end results database. Clin Lymphoma Myeloma Leuk. 2014, Supplement:S90–S95.

    Google Scholar 

  • Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet. 2016;388(10044):565–75.

    Article  CAS  PubMed  Google Scholar 

  • Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822–9.

    Article  CAS  PubMed  Google Scholar 

  • Horowitz J, Smith JL, Weber TK, Rodriguez-Bigas MA, Petrelli NJ. Postoperative complications after splenectomy for hematologic malignancies. Ann Surg. 1996;223(3):290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–65.

    Article  CAS  PubMed  Google Scholar 

  • Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, et al. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL younger trials. Leukemia. 2016;30(6):1428–30.

    Article  CAS  PubMed  Google Scholar 

  • Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma—target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.

    Article  PubMed  Google Scholar 

  • International Lymphoma Study Group. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909–18.

    Google Scholar 

  • Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL network. J Hematop. 2009;2(2):103–11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–31.

    Article  CAS  PubMed  Google Scholar 

  • Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German multicenter study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3861–73.

    Article  CAS  PubMed  Google Scholar 

  • Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 LyMa trial of the Lysa/Goelams group [internet]. Am Soc Hematology; 2016 [cited 2017 May 22]. Available from: http://www.bloodjournal.org/content/128/22/145.abstract.

  • Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. Limited-stage mantle-cell lymphoma. Ann Oncol. 2003;14(10):1555–61.

    Article  CAS  PubMed  Google Scholar 

  • Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol. 2005;23(9):1984–92.

    Article  CAS  PubMed  Google Scholar 

  • M’kacher R, Bennaceur A, Farace F, Laugé A, Plassa LF, Wittmer E, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene. 2003;22(39):7905–12.

    Article  PubMed  Google Scholar 

  • Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–13.

    Article  PubMed  Google Scholar 

  • Murthy V, Thomas K, Foo K, Cunningham D, Johnson B, Norman A, et al. Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. Clin Lymphoma Myeloma. 2008;8(4):241–5.

    Article  PubMed  Google Scholar 

  • National Comprehensive Cancer Network. NCCN guidelines non-Hodgkin lymphoma version 3, 2017 [Internet]; 2017 [cited 2017 May 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf.

  • Nygren L, Wennerholm SB, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012;119(18):4215–23. https://doi.org/10.1182/blood-2011-12-400580.

    Article  CAS  PubMed  Google Scholar 

  • Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. Surveillance, epidemiology, and end results (SEER) program SEER* Stat database: Incidence—SEER 9 Regs public-use, Nov 2004 Sub (1973–2002). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Released April 2005, based on the November 2004 submission; 2008.

    Google Scholar 

  • Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53.

    Article  CAS  PubMed  Google Scholar 

  • Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol. 2006;65(4):1185–91.

    Article  Google Scholar 

  • Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.

    Article  CAS  PubMed  Google Scholar 

  • Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma. 2011;52(3):387–93.

    Article  PubMed  Google Scholar 

  • Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone Immunochemotherapy followed by yttrium-90–Ibritumomab Tiuxetan in untreated mantle-cell lymphoma: eastern cooperative oncology group study E1499. J Clin Oncol. 2012;30(25):3119–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed.; 2008 [cited 2017 May 22], Available from: http://www.lenfomamyeloma.org.tr/folders/file/3_kongre_sunumlar/12mayis2012pdf/suheyla_bozkurt_12_mayis_2012.pdf.

  • Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008;113(10):2734–41.

    Article  CAS  PubMed  Google Scholar 

  • Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg. 2004;240(1):28–37.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yoong Y, Kurtin PJ, Allmer C, Geyer S, Habermann TM, Nagorney DM, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2001;42(6):1235–41.

    Article  CAS  PubMed  Google Scholar 

  • Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Muenster, Albert-Schweitzer Campus 1, Gebäude A1, 48419, Muenster, Germany

    Gabriele Reinartz & Kai Kröger

  2. Department of Medicine III, University of Munich-Grosshadern, Munich, Germany

    Tobias Weiglein & Martin Dreyling

Authors
  1. Gabriele Reinartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Weiglein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kai Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriele Reinartz .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany

    Frederik Wenz

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Reinartz, G., Weiglein, T., Kröger, K., Dreyling, M. (2017). Radiation Therapy in Mantle Cell Lymphoma. In: Wenz, F. (eds) Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-52619-5_55-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52619-5_55-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52619-5

  • Online ISBN: 978-3-319-52619-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation